CDER/CBER proprietary names meeting
Executive Summary
CDER and CBER will hold a public meeting June 5 to prepare for a pilot program on enabling pharmaceutical firms to evaluate proposed proprietary names and submit data generated from those evaluations to FDA for review (1"The Pink Sheet," Jan. 14, 2008, p. 15). The agenda includes a concept paper describing the logistics of the pilot program, proposed recommendations for carrying out a proprietary name review and the way FDA intends to review submissions. FDA plans to issue the concept paper by the end of this fiscal year and begin the pilot in FY 2009
You may also be interested in...
Brand Names In 2008: Can Industry Pilot Its Way Out Of Trouble?
Industry may shoulder some of the burden of testing proprietary drug names this year under a pilot program included in the renewal of the Prescription Drug User Fee Act, but with that may come some clarity in a subjective field that so far has lacked detailed guidance from FDA
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.